Bridging The Gap Between mAbs And Next-Generation Therapeutics

The inherent complexity of certain molecules, like bispecific antibodies and Fc-fusion proteins, can impose additional challenges during development when compared to monoclonal antibodies (mAbs). FUJIFILM Diosynth Biotechnologies' Apollo™ X expression system and associated technologies provide versatile solutions that are compatible with a diverse range of biotherapeutics including bispecific and Fc-fusion molecules. In this presentation, we demonstrate the system's ability to express these proteins efficiently through a streamlined development process.